Program
Valproic Acid
Also written as “Divalproex Sodium”, “divalproex sodium” and “Sodium valproate”.
Its studies are mostly in Bipolar Disorder · Epilepsy · Migraine Disorders · Seizures · Schizophrenia, led by 11 companies.
Drug pageValproic Acid: every studyMany companies study it; this page follows only the 38 they lead. All 261 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Abbottits history only | 100 open or running | phase 3since May 15, 2003 | May 15, 2003 | none ahead |
| Dr. Reddy's Laboratoriesits history only | 70 open or running | phase 1since Jan 25, 2010 | Jan 25, 2010 | none ahead |
| Sanofiits history only | 40 open or running | phase 4since Dec 9, 2005 | Dec 9, 2005 | none ahead |
| Teva Pharmaceutical Industriesits history only | 40 open or running | phase 1since Jan 30, 2009 | Jan 30, 2009 | none ahead |
| AstraZenecaits history only | 30 open or running | phase 4since Aug 29, 2005 | Apr 9, 2004 | none ahead |
| Novartisits history only | 30 open or running | phase 1since Mar 17, 2009 | Mar 17, 2009 | none ahead |
| Desitin Arzneimittelits history only | 20 open or running | phase 1since Dec 21, 2023 | Dec 21, 2023 | none ahead |
| Viatrisits history only | 20 open or running | phase 1since Mar 30, 2008 | Mar 30, 2008 | none ahead |
| Cerebral Therapeuticsits history only | 10 open or running | phase 2since Sep 3, 2016 | Sep 3, 2016 | none ahead |
| Hearthstone Alzheimer Careits history only | 10 open or running | phase 1since Sep 12, 2005 | Sep 12, 2005 | none ahead |
| Tecnoquimicasits history only | 10 open or running | phase 4since Apr 11, 2019 | Apr 11, 2019 | none ahead |
Also a collaborator on its studies: BioPharma Services.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 16 studies since May 15, 2003.
- Mar 25, 2008Phase 2 study in Pediatric EpilepsyAbbott · NCT00646711 · 16 enrolled · United States
- Mar 30, 2008Viatris’s first studies: 2 phase 1 studies in HealthyNew to ViatrisViatris · NCT00648076, NCT00647712
- Jan 30, 2009Teva Pharmaceutical Industries’ first studies: 2 phase 1 studies in HealthyNew to Teva Pharmaceutical IndustriesTeva Pharmaceutical Industries · NCT00834990, NCT00834639
- Mar 17, 2009Novartis’s first study: phase 1 study in SeizuresNew to NovartisNovartis · NCT00864006 · 28 enrolled
- Jun 2, 20092 phase 1 studies in EpilepsyNovartis · NCT00913874, NCT00913848
- Sep 9, 20092 phase 1 studies in HealthyTeva Pharmaceutical Industries · NCT00974441, NCT00974012
- Jan 25, 2010Dr. Reddy's Laboratories’ first studies: 2 phase 1 studies in HealthyNew to Dr. Reddy's LaboratoriesDr. Reddy's Laboratories · NCT01056627, NCT01055938
- May 26, 20103 phase 1 studies in HealthyDr. Reddy's Laboratories · NCT01132196, NCT01132183, NCT01132170
- Apr 4, 20122 phase 1 studies in HealthyDr. Reddy's Laboratories · NCT01581788, NCT01581775
- Sep 3, 2016Cerebral Therapeutics’ first study: phase 2 study in EpilepsyNew to Cerebral TherapeuticsCerebral Therapeutics · NCT02899611 · 6 enrolled · Australia
- Sep 14, 2018Phase 1 study in EpilepsySanofi · NCT03681158 · 5 enrolled · United Kingdom
- Apr 11, 2019Tecnoquimicas’ first study: phase 4 study in HealthyNew to TecnoquimicasTecnoquimicas · NCT03914534 · 30 enrolled · Colombia
- Dec 21, 2023Desitin Arzneimittel’s first study: phase 1 study in Food-drug InteractionNew to Desitin ArzneimittelDesitin Arzneimittel · NCT06211283 · 28 enrolled · Canada
- Jan 10, 2024Phase 1 study in Multiple Drug UseDesitin Arzneimittel · NCT06214130 · 22 enrolled · Canada
TargetBeta
“Succinate semialdehyde dehydrogenase inhibitor; Succinate semialdehyde dehydrogenase inhibitor; Succinate semialdehyde dehydrogenase inhibitor”ChEMBL 37, by rule
Studies
All 38 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06214130Multiple Drug Use · Canada | 1 | Completed | Desitin Arzneimittel | Nov 6, 2023 | 22 |
| NCT06211283Food-drug Interaction · Canada | 1 | Completed | Desitin Arzneimittel | Oct 20, 2023 | 28 |
| NCT03914534Healthy · Colombia | 4 | Completed | Tecnoquimicas | Jul 31, 2018 | 30 |
| NCT03681158Epilepsy · United Kingdom | 1 | Completed | Sanofi | Apr 11, 2019 | 5 |
| NCT02899611Epilepsy · Australia | 2 | Completed | Cerebral Therapeutics | Jun 1, 2021 | 6 |
| NCT01581788Healthy · India | 1 | Completed | Dr. Reddy's Laboratories | Feb 2011 | 54 |
| NCT01581775Healthy · India | 1 | Completed | Dr. Reddy's Laboratories | Jan 2011 | 54 |
| NCT01132196Healthy · India | 1 | Completed | Dr. Reddy's Laboratories | Sep 2006 | 34 |
| NCT01132183Healthy · India | 1 | Completed | Dr. Reddy's Laboratories | Mar 2007 | 34 |
| NCT01132170Healthy · India | 1 | Completed | Dr. Reddy's Laboratories | Sep 2006 | 34 |
| NCT01056627Healthy · India | 1 | Completed | Dr. Reddy's Laboratories | Jan 2007 | 34 |
| NCT01055938Healthy · India | 1 | Completed | Dr. Reddy's Laboratories | Jan 2007 | 34 |
| NCT00974441Healthy · United States | 1 | Completed | Teva Pharmaceutical Industries | Sep 2006 | 48 |
| NCT00974012Healthy · United States | 1 | Completed | Teva Pharmaceutical Industries | Oct 2006 | 24 |
| NCT00913874Epilepsy | 1 | Completed | Novartis | Oct 2005 | 30 |
| NCT00913848Epilepsy | 1 | Completed | Novartis | Oct 2005 | 30 |
| NCT00864006Seizures | 1 | Completed | Novartis | Oct 2006 | 28 |
| NCT00834990Healthy · United States | 1 | Completed | Teva Pharmaceutical Industries | Sep 2003 | 24 |
| NCT00834639Healthy · United States | 1 | Completed | Teva Pharmaceutical Industries | Sep 2003 | 24 |
| NCT00648076Healthy · United States | 1 | Completed | Viatris | Dec 2004 | 40 |
| NCT00647712Healthy · United States | 1 | Completed | Viatris | Dec 2004 | 38 |
| NCT00646711Pediatric Epilepsy · United States | 2 | Completed | Abbott | Dec 2003 | 16 |
| NCT00431522Bipolar Disorder · Turkey | 4 | Completed | Sanofi | Oct 2006 | 58 |
| NCT00271258Bipolar Disorder · France | 3 | Completed | Sanofi | 200 | |
| NCT00264173Bipolar Disorder | 4 | Completed | Sanofi | 270 | |
| NCT00195806Migraine Disorders · United States | 3 | Completed | Abbott | 315 | |
| NCT00195780Bipolar I Disorder · United States | 3 | Completed | Abbott | 227 | |
| NCT00195767Mania · United States | 3 | Completed | Abbott | 150 | |
| NCT00195754Migraine Disorders · United States | 3 | Completed | Abbott | 114 | |
| NCT00195741Migraine Disorders · United States | 3 | Completed | Abbott | 300 | |
| NCT00197834Dementia · United States | 1 | UNKNOWN | Hearthstone Alzheimer Care | 20 | |
| NCT00139074Bipolar Disorder · Denmark | 4 | Terminated | AstraZeneca | Jun 2006 | 17 |
| NCT00114686Alcoholism · United States | 3 | Completed | AstraZeneca | 350 | |
| NCT00102713Seizures · United States | 3 | Completed | Abbott | 50 | |
| NCT00081380Bipolar Disorder · United States, Canada | 3 | Completed | AstraZeneca | 710 | |
| NCT00067431Epilepsies, Partial · United States | 3 | Terminated | Abbott | 300 | |
| NCT00067262Bipolar Disorder · United States | 3 | Completed | Abbott | 150 | |
| NCT00060905Bipolar Disorder · United States | 3 | Completed | Abbott | 370 |
How it is read
Names in the registry
- “Divalproex Sodium”, 10 entries
- “divalproex sodium”, 7 entries
- “Sodium valproate”, 3 entries
- “Valproic Acid”, 2 entries
- “Valproic Acid 500 MG”, 2 entries
Conditions, from the studies’ own filings
- Bipolar Disorder, 9 studies
- Epilepsy, 7 studies
- Migraine Disorders, 3 studies
- Seizures, 2 studies
- Schizophrenia, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.